 David Binder
Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| CTLA-4 Antigen | 2 | 2015 | 104 | 0.820 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2018 | 264 | 0.800 |
Why?
| | Cancer Vaccines | 3 | 2014 | 160 | 0.750 |
Why?
| | Neoplasms, Experimental | 3 | 2014 | 173 | 0.560 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 5 | 2018 | 55 | 0.540 |
Why?
| | Flagellin | 1 | 2017 | 19 | 0.520 |
Why?
| | T-Lymphocytes | 4 | 2018 | 1982 | 0.510 |
Why?
| | B7-H1 Antigen | 2 | 2018 | 241 | 0.500 |
Why?
| | Immunotherapy | 3 | 2017 | 657 | 0.480 |
Why?
| | Salmonella typhimurium | 1 | 2017 | 190 | 0.450 |
Why?
| | Cell Cycle Checkpoints | 1 | 2015 | 99 | 0.440 |
Why?
| | Biliary Tract Neoplasms | 2 | 2025 | 31 | 0.420 |
Why?
| | Glioblastoma | 4 | 2018 | 353 | 0.410 |
Why?
| | Bacterial Vaccines | 1 | 2013 | 63 | 0.390 |
Why?
| | Melanoma, Experimental | 1 | 2013 | 108 | 0.380 |
Why?
| | Melanoma | 2 | 2017 | 761 | 0.360 |
Why?
| | Antigens, Neoplasm | 1 | 2013 | 272 | 0.350 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2018 | 154 | 0.340 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 917 | 0.250 |
Why?
| | Neoplasms | 3 | 2017 | 2884 | 0.240 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2019 | 389 | 0.240 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2018 | 199 | 0.230 |
Why?
| | Cholangiocarcinoma | 2 | 2025 | 106 | 0.230 |
Why?
| | Gallbladder Neoplasms | 1 | 2023 | 20 | 0.200 |
Why?
| | Medical Oncology | 1 | 2025 | 332 | 0.180 |
Why?
| | Bile Duct Neoplasms | 1 | 2023 | 128 | 0.170 |
Why?
| | Radiation Tolerance | 2 | 2019 | 103 | 0.170 |
Why?
| | Radioimmunotherapy | 1 | 2019 | 25 | 0.150 |
Why?
| | Animals | 14 | 2019 | 38109 | 0.150 |
Why?
| | Immunotherapy, Adoptive | 2 | 2013 | 337 | 0.150 |
Why?
| | Lymphocyte Depletion | 1 | 2019 | 132 | 0.150 |
Why?
| | Lymphocyte Activation | 2 | 2013 | 1126 | 0.140 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2018 | 29 | 0.140 |
Why?
| | STAT3 Transcription Factor | 1 | 2019 | 207 | 0.140 |
Why?
| | Brain Neoplasms | 2 | 2017 | 1322 | 0.130 |
Why?
| | Radiation, Ionizing | 1 | 2018 | 87 | 0.130 |
Why?
| | Cranial Irradiation | 1 | 2017 | 85 | 0.130 |
Why?
| | Liver Neoplasms | 1 | 2023 | 783 | 0.120 |
Why?
| | Colorectal Neoplasms | 1 | 2024 | 848 | 0.120 |
Why?
| | Kynurenine | 1 | 2017 | 114 | 0.120 |
Why?
| | Toll-Like Receptors | 1 | 2017 | 194 | 0.120 |
Why?
| | Tryptophan Oxygenase | 1 | 2015 | 33 | 0.120 |
Why?
| | Gadolinium DTPA | 1 | 2015 | 68 | 0.110 |
Why?
| | Mice | 10 | 2019 | 18365 | 0.110 |
Why?
| | Head and Neck Neoplasms | 1 | 2019 | 562 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 2018 | 826 | 0.110 |
Why?
| | Neovascularization, Pathologic | 2 | 2013 | 286 | 0.100 |
Why?
| | Prostate | 1 | 2015 | 158 | 0.100 |
Why?
| | Tumor Escape | 1 | 2013 | 49 | 0.100 |
Why?
| | Mice, Inbred C57BL | 5 | 2019 | 5997 | 0.100 |
Why?
| | HLA-A2 Antigen | 1 | 2013 | 35 | 0.100 |
Why?
| | Combined Modality Therapy | 3 | 2024 | 1268 | 0.100 |
Why?
| | HLA-D Antigens | 1 | 2013 | 30 | 0.100 |
Why?
| | Ovalbumin | 1 | 2013 | 190 | 0.100 |
Why?
| | Tissue Array Analysis | 1 | 2012 | 50 | 0.090 |
Why?
| | Myeloid Cells | 1 | 2013 | 148 | 0.090 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 735 | 0.090 |
Why?
| | Contrast Media | 1 | 2015 | 488 | 0.090 |
Why?
| | Antigen Presentation | 1 | 2013 | 205 | 0.090 |
Why?
| | Interleukin-15 | 1 | 2012 | 97 | 0.090 |
Why?
| | T-Lymphocyte Subsets | 1 | 2013 | 415 | 0.090 |
Why?
| | Microvessels | 1 | 2012 | 99 | 0.090 |
Why?
| | Epitopes | 1 | 2013 | 485 | 0.080 |
Why?
| | Prognosis | 2 | 2017 | 4293 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2018 | 930 | 0.080 |
Why?
| | Macrophages | 2 | 2019 | 1511 | 0.080 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 285 | 0.080 |
Why?
| | Peptide Fragments | 1 | 2013 | 699 | 0.070 |
Why?
| | Cell Line, Tumor | 4 | 2018 | 3550 | 0.070 |
Why?
| | Neoplasm Metastasis | 2 | 2024 | 695 | 0.070 |
Why?
| | Killer Cells, Natural | 1 | 2012 | 469 | 0.070 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2019 | 223 | 0.070 |
Why?
| | Humans | 14 | 2025 | 144957 | 0.070 |
Why?
| | Female | 7 | 2024 | 78376 | 0.070 |
Why?
| | Adenocarcinoma | 1 | 2012 | 931 | 0.060 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 978 | 0.060 |
Why?
| | Immunologic Memory | 2 | 2019 | 366 | 0.050 |
Why?
| | Mice, Knockout | 3 | 2018 | 3125 | 0.050 |
Why?
| | Brain | 1 | 2017 | 2941 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2025 | 421 | 0.050 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2023 | 63 | 0.050 |
Why?
| | Disease Models, Animal | 3 | 2018 | 4569 | 0.050 |
Why?
| | Signal Transduction | 1 | 2015 | 5233 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2019 | 39 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 80 | 0.040 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2019 | 72 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 202 | 0.040 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2019 | 178 | 0.040 |
Why?
| | Mice, Nude | 1 | 2019 | 688 | 0.030 |
Why?
| | Immunomodulation | 1 | 2018 | 101 | 0.030 |
Why?
| | Radiotherapy | 1 | 2018 | 206 | 0.030 |
Why?
| | Drug Synergism | 1 | 2018 | 357 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1253 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2019 | 1311 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2017 | 246 | 0.030 |
Why?
| | Age Distribution | 1 | 2017 | 403 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2018 | 768 | 0.030 |
Why?
| | Male | 6 | 2024 | 72406 | 0.030 |
Why?
| | Middle Aged | 4 | 2024 | 35928 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 769 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 2015 | 200 | 0.030 |
Why?
| | Adult | 4 | 2024 | 40506 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 966 | 0.030 |
Why?
| | Immunity | 1 | 2015 | 139 | 0.030 |
Why?
| | Catalysis | 1 | 2015 | 322 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2024 | 11695 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1385 | 0.030 |
Why?
| | Epithelium | 1 | 2015 | 314 | 0.030 |
Why?
| | Tryptophan | 1 | 2015 | 181 | 0.030 |
Why?
| | Skin Window Technique | 1 | 2013 | 2 | 0.030 |
Why?
| | Receptors, Chemokine | 1 | 2013 | 47 | 0.030 |
Why?
| | Microscopy, Fluorescence | 1 | 2015 | 418 | 0.030 |
Why?
| | CD11b Antigen | 1 | 2013 | 60 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2018 | 1465 | 0.030 |
Why?
| | Models, Animal | 1 | 2015 | 392 | 0.030 |
Why?
| | Mice, Inbred C3H | 1 | 2013 | 251 | 0.020 |
Why?
| | Cross-Priming | 1 | 2013 | 16 | 0.020 |
Why?
| | Radiography | 1 | 2015 | 845 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1786 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 434 | 0.020 |
Why?
| | Tumor Burden | 1 | 2013 | 322 | 0.020 |
Why?
| | Inclusion Bodies | 1 | 2012 | 27 | 0.020 |
Why?
| | Microcirculation | 1 | 2012 | 138 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2018 | 936 | 0.020 |
Why?
| | Immunization | 1 | 2013 | 374 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2012 | 309 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1486 | 0.020 |
Why?
| | Aged | 3 | 2017 | 25947 | 0.020 |
Why?
| | Oligopeptides | 1 | 2013 | 269 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1462 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2013 | 524 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 851 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 1135 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2017 | 2832 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1173 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1718 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2185 | 0.020 |
Why?
| | Biomarkers | 1 | 2018 | 4275 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1500 | 0.010 |
Why?
| | Models, Biological | 1 | 2013 | 1822 | 0.010 |
Why?
| | Biomarkers, Tumor | 1 | 2012 | 1322 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8279 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2015 | 3869 | 0.010 |
Why?
|
|
Binder's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|